BUZZ-Palatin Technologies Inc: Rival drug maker Sprout being bought by Valeant
** Specialty drug maker's shares up 16 pct at $1.13 premarket after Canada's Valeant Pharmaceuticals International Inc says it will buy Sprout Pharmaceuticals
** Palatin is creating drug, called bremelanotide, that could rival Sprout's drug, Addyi, which became first approved treatment this week for low sexual desire in premenopausal women
** Approval for Sprout's drug seen by industry experts as more likely to help build market for better future rival drugs
** Valeant's U.S-listed shares up 0.4 pct at $245.92 premarket
** Up to Wednesday's close, stock had risen 33 pct this year
© Thomson Reuters 2017 All rights reserved.